The Swedish MPA conducted an on-site visit at Skåne University Hospital in December, the facilities were approved, thus enabling iCoat Medical to commence the First in Human – trial ATMIRe. This was the final approval from the authorities, and we have the operational preparations in place. Thus, iCoat Medical officially transfers into a clinical-stage pharmaceutical company. Enrollment of the first patient is expected during Q1 2022.

 

“This is an exciting time for us and a milestone in the development of the company. We are well prepared for the clinical study and pre-clinical work for other clinical indications is ongoing. We are now accelerating our development to become one of the leading companies within innate immunology with a clear focus on ischemia reperfusion injuries” says iCoat Medical’s CEO Peder Waern.

 

For more information, please contact:

Peder Waern, CEO, iCoat Medical AB

E-mail: peder.waern@icoatmedical.com